Variant · Other
KRAS Mutation
CI-VAR-00002669Explore in graph →CIViC 336
Curated evidence
Evidence by cancer (66 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24166148
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Endometrial Neoplasm1 | ||||||||
| KRAS Mutation | Ridaforolimus + TemsirolimusSubstitutes | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID89494 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tum… (full text at CIViC) PMID 24166148 · Mackay et al., 2014 · Open in CIViC | civic |
| Malignant Neoplasm5 | ||||||||
| BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation | Selumetinib | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID11696In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available